House committee investigates FDA’s handling of common nasal decongestant as efficacy questions loom
04 Dec 2023
A House panel is probing the FDA over how it has allowed a common ingredient in over-the-counter cold medications to stay on the market for decades after new data suggested that it doesn’t work to treat nasal congestion.
In a letter sent to FDA Commissioner Rob Califf dated Sunday, Rep. Lisa McClain (R-MI), who chairs the House Oversight subcommittee on healthcare, asks the FDA to schedule a briefing with committee staff to glean more information on the agency’s handling of oral phenylephrine, the active ingredient in several cold medicines like Sudafed and Theraflu.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.